Navigation Links
PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
Date:12/6/2011

MANSFIELD, Mass., Dec. 6, 2011 /PRNewswire/ -- PrimeraDx today announced that Leroy Hood, MD, PhD, a world recognized leader in the molecular device industry, has been appointed to its Scientific Advisory Board. 

"High multiplex qPCR diagnostics is a key step in bringing personalized medicine to the clinic," commented Dr. Hood.  "I am delighted to help PrimeraDx take the step from an innovative next generation qPCR platform to a robust molecular diagnostics solution."

"Lee brings a breadth of knowledge in the molecular device industry that no one else has.  With Lee's scientific vision we will move forward with our goal of transforming molecular diagnostic medicine and improving patient care," said President and CEO Matthew McManus.

Dr. Hood has established a systems approach to understanding the complexity of biology and medicine.  He has played a pivotal role in the DNA sequencing industry and his innovations were essential for the sequencing of the human genome.  Dr. Hood has been instrumental in the founding of numerous research and commercial enterprises, including Applied Biosystems, Amgen and the Institute for System Biology, where he currently holds the position of President.  He has won several awards and accolades, including; the 2003 AMP award for excellence in Molecular Diagnostics, the Academy of Engineering's Russ Prize, the Lasker Award and the Kyoto Prize.  Dr. Hood has more than 700 peer reviewed articles and is a member of the National Academy of Sciences, the National Academy of Engineering and the Institute of Medicine.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative answers to the clinic.  The company is pursuing a two pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
2. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
3. Ulthera Appoints Greg Waller as Chief Financial Officer
4. Tengion Appoints John L. Miclot President and Chief Executive Officer
5. Remedi SeniorCare® Appoints Corey Gauff SVP of Sales and Account Management
6. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
7. CVS Caremark Appoints Kevin Murphy President of Accordant Business
8. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
9. Adeona Appoints Jeff Lucero Riley as Independent Chairman
10. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
11. InterMune Appoints Angus C. Russell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):